|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2003-7-25
|
|
pubmed:abstractText |
5-Fluorouracil (5-FU), doxorubicin and methotrexate (FAMTX) and cisplatin, epirubicin, leucovorin and 5-FU (PELF) have both been reported to be superior to the combination 5-FU, doxorubicin and mitomycin C (FAM) in advanced gastric carcinoma. On the basis of the presence and dose intensity of the included agents, we hypothesised that PELF would be superior to FAMTX.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
pubmed-author:BisagniGG,
pubmed-author:CamisaRR,
pubmed-author:CanalettiRR,
pubmed-author:CarliniPP,
pubmed-author:CocconiGG,
pubmed-author:CognettiFF,
pubmed-author:Di CostanzoFF,
pubmed-author:GamboniAA,
pubmed-author:GasperoniSS,
pubmed-author:Italian Oncology Group for Clinical Research,
pubmed-author:PorrozziSS,
pubmed-author:PucciFF,
pubmed-author:RodinòCC,
pubmed-author:RuggeriE MEM,
pubmed-author:ZironiSS
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1258-63
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12881389-Adenocarcinoma,
pubmed-meshheading:12881389-Adult,
pubmed-meshheading:12881389-Aged,
pubmed-meshheading:12881389-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12881389-Cisplatin,
pubmed-meshheading:12881389-Confidence Intervals,
pubmed-meshheading:12881389-Dose-Response Relationship, Drug,
pubmed-meshheading:12881389-Doxorubicin,
pubmed-meshheading:12881389-Drug Administration Schedule,
pubmed-meshheading:12881389-Epirubicin,
pubmed-meshheading:12881389-Female,
pubmed-meshheading:12881389-Fluorouracil,
pubmed-meshheading:12881389-Humans,
pubmed-meshheading:12881389-Italy,
pubmed-meshheading:12881389-Leucovorin,
pubmed-meshheading:12881389-Male,
pubmed-meshheading:12881389-Methotrexate,
pubmed-meshheading:12881389-Middle Aged,
pubmed-meshheading:12881389-Neoplasm Invasiveness,
pubmed-meshheading:12881389-Neoplasm Staging,
pubmed-meshheading:12881389-Probability,
pubmed-meshheading:12881389-Prognosis,
pubmed-meshheading:12881389-Stomach Neoplasms,
pubmed-meshheading:12881389-Survival Analysis,
pubmed-meshheading:12881389-Treatment Outcome
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma.
|
|
pubmed:affiliation |
Medical Oncology Division, Azienda Ospedaliera Universitaria, Parma, Italy. giorgio.cocconi@tin.it
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Multicenter Study
|
